COPD Clinical Presentation

COPD

is primarily caused by long-term exposure to toxic gases, most commonly cigarette smoke

Chronic Bronchitis

 Defined clinically as a chronic, productive cough for at least 3 months in 2 consecutive years. It features goblet cell hyperplasia, mucus hypersecretion, and chronic inflammation of the small airways, leading to cyanosis and fluid retention

Emphysema ("Pink Puffers")

Defined anatomically by the destruction of alveolar walls and permanent enlargement of air spaces distal to the terminal bronchioles. This destroys lung elasticity, causing air trapping and a characteristic "barrel chest" appearance

Alpha-1 Antitrypsin (AAT)

Genetic factor on non-smokers who develop emphysema is ‘blank’ deficiency, an enzyme inhibitor that normally protects lung tissue from neutrophil elastase damage

Spirometry

Diagnostic Test: Post-bronchodilator ‘blank’ is the gold standard. A FEV1/FVC ratio < 0.70 confirms irreversible airflow limitation.

GOLD 1 (Mild)

FEV1 ≥ 80% predicted

GOLD 2 (Moderate)

• 50% ≤ FEV1 < 80% predicted

GOLD 3 (Severe)

30% ≤ FEV1 < 50% predicted

GOLD 4 (Very Severe)

FEV1 < 30% predicted

Cellular Recruits

The primary immune cells involved in COPD are Neutrophils, Macrophages, and CD8+ T-lymphocytes. (PHLE Contrast: Asthma primarily involves Eosinophils and Mast cells)

Inflammatory Mediators

These activated cells release a wave of destructive inflammatory cytokines, specifically Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-α), and Leukotriene B4 (LTB₄)

CHRONIC BRONCHITIS (Blue Bloater)

• Chronic, productive cough

• Purulent sputum

• Hemoptysis

• Mild dyspnea initially

• Cyanosis - (due to hypoxemia)

• Peripheral edema -(due to cor pulmonale/right sided heart failure)

• Crackles, wheezes

• Prolonged expiration

• Obese

EMPHYSEMA Pink Puffer

• Dyspnea

• Minimal cough

• Increased minute ventilation

• Pink skin, pursed-lip breathing

• Accessory muscle use - _{^{permanent alveolar destruction, thus difficulty in breathing}}

• Cachexia

• Hyperinflation, barrel chest - _{^{barrel chest or enlargement of chest (increased lung size) due to accessory muscle use}}

• Decreased breath sounds

• Tachypnea

Chronic bronchitis: complications

Secondary polycythemia vera due to hypoxemia

Pulmonary hypertension due to reactive vasoconstriction from hypoxemia

Cor pulmonale from chronic pulmonary hypertension

Emphysema: complications

Pneumothorax due to bullae

Weight loss due to work of breathing

TREATMENT GOALS

• Prevent disease

• Relieve symptoms and improve exercise tolerance

• Improve health status

• Prevent & treat exacerbations

• Prevent & treat complications

• Reduce mortality

STRATEGIES FOR COPD TREATMENT

COPD responds to bronchodilators, including beta-2 agonists and muscarinic antagonists, but is less responsive to corticosteroids than asthma.

A combination long-acting beta-2 agonist with a long acting muscarinic blocker, given by inhalation, is often preferred for prophylaxis

Antibiotic therapy is more important in COPD than in asthma.

COPD: suggestive features

Onset in mid-life

Symptoms slowly progressive _{^{(irreversible)}}

History of tobacco smoking or exposure to other types of smoke

Congestive Heart Failure

Chest X-ray shows dilated heart, pulmonary edema

Pulmonary function tests indicate volume restriction, not airflow limitation

Bronchiectasis

Large volumes of purulent sputum

Commonly associated with bacterial infection

Chest X-ray/CT shows bronchial dilation, bronchial wall thickening

Tuberculosis

Onset all ages

Chest X-ray shows lung infiltrate

Microbiological confirmation

High local prevalence of tuberculosis

Obliterative Bronchiolitis

Onset at younger age, nonsmokers

May have history of rheumatoid arthritis or acute fume exposure

Seen after lung or bone marrow transplantation

CT on expiration shows hypodense areas

Diffuse panbronchiolitis

Predominantly seen in patients of Asian descent

Most patients are male and nonsmokers

Almost all have chronic sinusitis

Chest X-ray & HRCT show diffuse small centrilobular nodular opacities & hyperinflation - _{^{We can see in the chest x-ray, there are portions that have black spots}}

Smoking cessation

‘blank’ is key. Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates. Legislative and smoking bans and counseling, delivered by healthcare professionals improve quit rates.

Individualized

Each pharmacological treatment regimen should be ‘blank’ and guided by the severity of symptoms, risk of exacerbations, side effects, comorbidities, drug availability and cost, and the patient’s response, preference, and ability to use various drug delivery devices

influenza vaccine and pneumococcal vaccines

Usually when the patient is categorized under Group A based on GOLD treatment guidelines, ‘blank’ and ‘blank’ are given

Influenza vaccination

‘blank’ decreases the incidence of lower respiratory tract infections

Pneumococcal vaccination

decreases lower respiratory tract infections

Pulmonary rehabilitation

improves symptoms, quality of life, and physical and emotional participation in everyday activities

Palliative approaches

‘blank’ are effective in controlling symptoms in advanced COPD.

Influenza vaccination

reduces serious illness and death in COPD patients

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients aged <65 with an FEV1 < 40% predicted and in those with comorbidities